The DKK1 Knockout NCI-H1299 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human non-small cell lung cancer cell line NCI-H1299. This product offers a heterogeneous pool of cells with targeted disruption of the DKK1 gene, enabling loss-of-function analysis of the secreted Wnt antagonist Dickkopf-1. The polyclonal format retains the genetic diversity of the original cell population, avoiding clonal selection bias while facilitating study of DKK1-dependent phenotypes in processes such as Wnt/??-catenin signaling modulation, cell proliferation, and metastasis.
The NCI-H1299 host cell line originates from a lymph node metastasis of a lung adenocarcinoma and is a well-established model for NSCLC. It features wild-type KRAS and a p53-null background, offering a unique system to investigate p53-independent tumorigenesis and crosstalk between Wnt and other oncogenic pathways. The epithelial origin and metastatic heritage make it particularly relevant for examining DKK1’s roles in migration, invasion, and epithelial-mesenchymal transition (EMT).
DKK1 encodes Dickkopf-1, a secreted inhibitor of canonical Wnt/??-catenin signaling. It binds to LRP5/LRP6 co-receptors in concert with KREMEN1/2, triggering internalization of the receptor complex and preventing Wnt ligand (e.g., WNT3A) from initiating signal transduction. This blockade prevents ??-catenin stabilization, thereby repressing key target genes such as AXIN2 and MYC. DKK1 is transcriptionally regulated by factors including TP53, TGFB1, MYC, and SNAI1, and crosstalks with MAPK/ERK and PI3K/AKT pathways, impacting cell proliferation, differentiation, and apoptosis.
In the NCI-H1299 context, DKK1 knockout provides a platform to explore its functions in a p53-null, KRAS wild-type setting. Since DKK1 is controlled by EMT drivers like SNAI1 and TGFB1, this model is apt for studying EMT dynamics and Wnt pathway switching during lung adenocarcinoma progression. The polyclonal nature of the knockout pool captures phenotypic heterogeneity relevant to metastasis, complementing the cell line’s lymph node origin. Applications include assessing drug sensitivity changes, particularly to PI3K/AKT or MAPK pathway inhibitors.
Typical experiments with these cells encompass Western blotting for ??-catenin and its targets, RT-qPCR for Wnt-responsive genes (e.g., AXIN2, MMP7), and TOPFlash/FOPFlash reporter assays to measure TCF/LEF activity. Functional assays such as MTT and transwell migration/invasion assess proliferation and motility, while flow cytometry for Annexin V detects apoptosis. Co-immunoprecipitation can confirm altered DKK1-LRP5/6 interactions. These capabilities support research into lung cancer growth, bone metastasis, EMT, and therapeutic resistance. For further inquiries, please contact Ascent Research.
